Recently, a hydrogel consisting of high-molecular-weight hyaluronic acid (HMW-HA) and an inhibitory fibronectin peptide Arg-Gly-Asp-Ser (RGDS) was developed as therapeutic strategy in GBM treatment. This evidence concerns the gene FN1 and glioblastoma.